ArticleFrontiers in oncology2026
Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is among the most commonly diagnosed malignant neoplasms of the female reproductive system, with peak incidence occurring in the perimenopausal and postmenopausal periods. The pathogenesis of this disease is multifactorial and associated with several well-established risk factors, including hormonal imbalance, obesity, and late onset of menopause. We report the case of a 64-year-old woman diagnosed with grade I endometrioid adenocarcinoma, stage IA according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification. The patient initially underwent total laparoscopic hysterectomy with bilateral salpingo-oophorectomy. More than three years after surgery, disease recurrence was detected during routine follow-up. Subsequent molecular analysis revealed a loss-of-function mutation in the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.